XSTO
LPGO
Market cap94kUSD
May 18, Last price
0.00SEK
Name
Lipigon Pharmaceuticals AB
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
97.94%
Rev. gr., 5y
42.63%
Revenues
0k
-100.00%
Net income
-32m
L+28.40%
CFO
-36m
L+44.36%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Lipigon Pharmaceuticals AB (publ), a company based in Umeå, Sweden, specializes in the development of therapeutic solutions for lipid-related disorders. Their innovative pipeline includes the Lipisense project, designed to address severe hypertriglyceridemia (SHTG) and familial chylomicronemia syndrome (FCS). Additionally, they are advancing a gene therapy program for lipodystrophy, a rare condition marked by atypical fat distribution throughout the body. Their work also extends to developing treatments for dyslipidemia, a general lipid imbalance, and an RNA drug candidate for acute respiratory distress syndrome (ARDS). In a strategic collaboration with HitGen Inc., Lipigon is also involved in creating small molecule therapies aimed at dyslipidemia, cardiovascular ailments, and other metabolic conditions. The firm, established in Umeå, Sweden, began its operations in 2010.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||